Aeolus Pharmaceuticals, Inc. has been invited to present data on the progress of the company’s contract with the Biomedical Advanced Research and Development Authority (BARDA) at the upcoming LD Micro Invitational Conference. The presentation will be focused on Aeolus’ lead compound AEOL 10150, which is designed to treat the pulmonary effects of acute radiation exposure (Lung-ARS) due to a nuclear event, as well as treat other diseases such as idiopathic pulmonary fibrosis.
Aeolus’ Chairman and CFO, David C. Cavalier will host the presentation, which will take place on Tuesday, June 2nd at 2:30 pm EDT at the Luxe Sunset Boulevard Hotel in Los Angeles, during which he will give an overview of the development programs being undertaken as part of the company’s contract with BARDA. The agreement includes $118.4 million in funding and is being invested to fund development costs of Aeolus’ studies.
The company’s lead compound being developed through the BARDA contract, AEOL 10150, is an investigational catalytic antioxidant for patients who are suffering the effects of being exposed to acute nuclear radiation. The treatment addresses the pulmonary effects of radiation exposure by neutralizing the reactive oxygen and nitrogen species, decreasing the oxidative stress, inflammation and tissue damage-signaling cascades.
AEOL 10150, which is one of the main points of Cavalier’s presentation, has already been successfully studied in preclinical and non-clinical studies in acute radiation-induced lung injury models that revealed its statistic relevance in improving survival. It was also well-tolerated in two human clinical trials, and Aeolus expects the drug to make a significant impact on patients who were exposed to high-doses of radiation during a nuclear event or cancer treatment.
Most recently, the company released positive data from research involving non-human primates (NHPs), demonstrating that after 60 days of treatment with AEOL 10150 there was an improvement in survival from 25% to 50%, which means it doubled the survival at 180 days after radiation exposure to the lungs. The U.S. Food and Drug Administration (FDA) has also already granted the therapy orphan drug designation to treat Lung-ARS and idiopathic pulmonary fibrosis.